Implantable Device May Minimize Chemotherapy Side Effects

An implantable device that directly delivers chemotherapy right to the site of tumors may more effectively treat pancreatic cancer with far fewer side effects.

Most forms of chemotherapy today are given via intravenous injection, meaning the drug must travel through much of the body before it reaches the site of the cancer, negatively impacting other organs and causing a host of nasty side effects.

The device, which has been developed by scientists at the Massachusetts Institute of Technology and Massachusetts General Hospital, is made from a flexible polymer film containing a chemotherapy agent that can be rolled into a tube, put into a catheter and implanted next to the pancreas. It then unfolds and can just cover the tumor itself, making it very targeted.

The film itself is designed to release drugs over a certain period of time and only on the side that touches the tumor, minimizing potential side effects since the chemotherapy doesn’t reach other organs.

The team focused on pancreatic cancer since it is one of the most difficult organs for chemotherapy to reach. It is also the third leading cause of cancer death in the US with a 5-year overall survival rate of just 6%. In addition, the pancreas has relatively few blood vessels, making it hard for drugs to reach inside.

As of now, the efficacy of the device has only been tested on rodents. However, recent study resultsshow promise for the technology. In the study, researchers used mice with transplanted human pancreatic tumors in them.

One group received the popular chemotherapy drug paclitaxel inserted into the device, while the other group also got paclitaxel, though delivered intravenously over four weeks, similar to standard chemotherapy treatment in humans.

Tumors in the rodents with the implants shrank more compared to tumors in the group that received the standard chemotherapy regimen. Even more remarkable, in the implant group, in some rats saw their tumors disappear completely.

The researchers also noted that the film acted as a kind of barrier to prevent the drug from harming other organs. And after 4 weeks, the concentration of paclitaxel in tumors in the implant group was 5 times higher than in the intravenous-treated rats.

Researchers are currently designing a trial of the device for a human trial, and note that the technology could potentially expand to treat other hard-to-reach tumors such as those in the gastrointestinal tract.

Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.

Did you find this article helpful?

Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement